Investment Rating - The report maintains a "Recommended" rating for the company [6] Core Insights - The company achieved a revenue of 1.62 billion yuan in 2024, representing a year-on-year growth of 57.2%, and a net profit of 400 million yuan, with a year-on-year increase of 145.9% [1] - The company is expected to continue its high growth trend due to ongoing capacity expansion and strategic partnerships in various global markets [2][3] - The expiration of key GLP-1 drug patents presents opportunities for the company to leverage existing customer resources for further market expansion [4] Summary by Relevant Sections Financial Performance - In 2024, the company reported a revenue of 1.625 billion yuan, with a growth rate of 57.2% compared to the previous year [5] - The net profit attributable to shareholders reached 400 million yuan, marking a significant increase of 145.7% year-on-year [5] - Forecasts for 2025 and 2026 predict revenues of 2.391 billion yuan and 3.086 billion yuan, with growth rates of 47.2% and 29.1% respectively [5] Capacity Expansion - The company has successfully built a new peptide workshop with a capacity of 5 tons per year, and another workshop is expected to be completed in the first half of 2025, adding another 5 tons per year [2] - The new formulation factory has achieved an annual production capacity of 4.5 billion capsules, with further expansions planned [2] Market Development - The company has established multiple strategic partnerships across various regions, including Europe, North America, South America, and India, enhancing its market presence and commercial capabilities [3] - Collaborations include agreements for the supply of raw materials for key drugs like semaglutide and liraglutide, indicating strong demand and growth potential [3] Future Outlook - The company is projected to achieve a net profit of 571 million yuan in 2025 and 781 million yuan in 2026, with corresponding growth rates of 42.6% and 36.8% [5] - The expected price-to-earnings ratios for 2025 and 2026 are 21 and 15 times, respectively, suggesting a favorable valuation outlook [4][5]